Sanofi partners with Cheplapharm on mature medicines portfolio

Paris - Pharmaceutical giant Sanofi (EURONEXT:SAN, NASDAQ: SNY) announced a strategic partnership with German-based family-owned company Cheplapharm. As part of the agreement, Sanofi will acquire 20 mature medicines and three manufacturing sites from Cheplapharm, in exchange for a 26.4% equity stake in the company. Lovenox/Clexane (enoxaparin) will be transferred, excluding the U.S. market.

Manufacturing sites in Hungary, Singapore, and France will join Cheplapharm, maintaining their existing employment arrangements and collective agreements. The commercial transfer of the medicine portfolio is set to begin in the first quarter of 2027, followed by the transfer of the sites. The transaction, subject to employee consultation, regulatory approvals, and customary closing conditions, is expected to be fully completed by the third quarter of 2027.

Sanofi's Executive Vice President of General Medicines, Thomas Grenier, highlighted the partnership's significance, which builds on a collaboration that began in 2014. Cheplapharm Co-CEOs Edeltraud Lafer and Sebastian Braun described the agreement as a major milestone for their company. Sanofi stated the proposed transaction will not impact its financial guidance for 2026, with additional financial details to be provided later.

Cheplapharm, with investments exceeding €6.2 billion since its inception, holds 3,440 marketing authorizations across 160 countries.